New Antidepressant Brintellix OKd

Tuesday, 01 Oct 2013 11:29 AM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink
The U.S. Food and Drug Administration approved Lundbeck's antidepressant Brintellix to treat adults with major depressive disorder.

The drug, which Lundbeck will co-market with Japanese partner Takeda Pharmaceutical Co Ltd, will be available in four doses.
 
Brintellix, like other antidepressants, will carry a boxed warning alerting patients and doctors to an increased risk of suicidal thoughts and behavior in children, adolescents and young adults aged 18-24 during initial treatment.
 
The most common side effects reported by patients taking the drug — generically known as vortioxetine — include nausea, constipation and vomiting.

Major depressive disorder is characterized by mood changes that may interfere with a person's ability to carry out to day-to-day activities. Symptoms also include increased fatigue and feelings of guilt or worthlessness.

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

Two 'Breakthrough' Drugs for Lung Disease

Thursday, 16 Oct 2014 12:40 PM

Roche Holding AG (ROG) and Boehringer Ingelheim GmbH won approval for the first therapies in the U.S. to treat the deadl . . .

Drug Fights Chemo Nausea

Tuesday, 14 Oct 2014 12:24 PM

The combination drug Akynzeo (netupitant and palonosetron) has been approved by the U.S. Food and Drug Administration to . . .

Drug-Coated Catheter Clears Blocked Leg Arteries

Tuesday, 14 Oct 2014 12:20 PM

The first drug-coated balloon catheter designed to clear narrowed or blocked arteries in the thigh and knee has been app . . .

Most Commented

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved